Evidence mapPaperPMID 40370423Full record

ReviewFrontiers in ophthalmology2025

The burden of illness in thyroid eye disease: current state of the evidence.

Madhura A Tamhankar, Syed Raza, Erika Brutsaert, Estefanía Urdániz, Yelena Vainilovich, Anne Heyes, Liesl Gildea, Marco Sales-Sanz

Abstract readReview
In one paragraph

Review in Frontiers in ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Madhura A TamhankarScheie Eye Institute, University of Pennsylvania, Philadelphia, PA, United States.
Syed RazaGlobal Health Economics and Outcome Research, argenx, Gerrards Cross, United Kingdom.
Erika BrutsaertClinical Development, argenx, Boston, MA, United States.
Estefanía UrdánizTranslational & Clinical Sciences, argenx, Ghent, Belgium.
Yelena VainilovichClinical Development, argenx, Ghent, Belgium.
Anne HeyesValue and Access, RTI Health Solutions, Manchester, United Kingdom.
Liesl GildeaValue and Access, RTI Health Solutions, Manchester, United Kingdom.
Marco Sales-SanzOculoplastic Surgery Unit, Ophthalmology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Thyroid eye disease (TED) is a disabling autoimmune condition characterized by proptosis and progressive orbital inflammation involving the extraocular muscles, orbital fat, and connective tissues. Clinical features include facial disfigurement, diplopia, dry eyes, and in severe cases, vision loss. Consequently, individuals with TED suffer significant physical and psychological burdens that impact their quality of life. Currently, there is no standardized definition or Methods: To describe the current understanding of TED epidemiology, diagnosis, disease burden, and recent TED treatment guidelines, a targeted literature review was conducted, searching multiple databases using key words of specific search topics (i.e., TED; epidemiology, humanistic, economic, and clinical burden; treatment; and practice guidelines) for articles published between October 2013 and October 2023 in the United States, United Kingdom, and Europe (France, Germany, Italy, and Spain). Articles published between May 2014 and May 2024 describing diverse racial and sociodemographic presentations of TED were included. Results: TED is a complex disease with an array of risk factors, including thyroid dysfunction, thyroid-stimulating immunoglobin, smoking, and comorbid conditions. The natural history of TED is not clearly defined, and diagnosis is complicated due to the array of phenotypes and orbital symptoms observed. Although novel first-line treatments are available in select countries, there is an unmet need for improved treatments for moderate-to-severe and sight-threatening TED. Individuals with TED continue to experience poor health-related quality of life due to the clinical burden that TED imposes along with large healthcare resource utilization costs and treatment costs, and economic evaluation studies are limited. Importantly, there is still a need for studies that explore diverse populations and the impact of race and ethnicity on the disease landscape. Conclusion: TED remains an incompletely characterized disease with major knowledge gaps, particularly among historically underserved populations.

Indexed as

autoimmune diseaseGraves ophthalmopathyGraves orbitopathyorbital conditionthyroid-associated ophthalmopathythyroid eye disease

Identifiers

PMID40370423
PMCPMC12075187

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.